DOCSLIB.ORG

High Risk Medications and Safe Treatment Alternatives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
High Risk Medications and Safe Treatment Alternatives Use of High-Risk Medications in the Elderly and Safer Alternate Treatments Certain medications are more likely to have adverse effects for people over the age of 65. There are often safer alternate treatments that are highly effective. Below is a list of high risk medications compiled by the PHP Plan Pharmacist. These are the medications included in the Plan formulary, as well as potential risks and alternative treatment options. Please consider these recommendations when prescribing for patients 65 and older. The Use of High-Risk Medications in the Elderly is a HEDIS (Healthcare Effectiveness Data and Information Set) performance measure that assesses the percentage of Plan Members 65 years of age and older who received at least one or two different high-risk medications. Therapeutic Class High Risk Medications Potential Risks Safer Treatment Options† Alpha-Blockers, Central Guanabenz May cause bradycardia, sedation, ACE inhibitors / ARBs Guanfacine orthostatic hypotension, and Beta-blockers Methyldopa exacerbate depression. Calcium channel blockers Reserpine (>0.1 mg/day) Thiazide diuretics Anti-Anxiety Agents Meprobamate Meprobamate has a high risk of Buspirone abuse, and is highly sedating. Use SSRIs (Fluoxetine, Citalopram, in the elderly may result in Paroxetine) confusion, falls/fractures,and SNRIs (Venlafaxine, duloxetine) respiratory depression. Anti-emetics Promethazine Elderly patients are more For N/V: Ondansetron (QL = 45/30) Trimethobenzamide (Tigan) susceptible to anticholinergic adverse events including urine retention, confusion, and sedation. Antiparkinson Agents Benztropine Elderly patients are more Carbidopa / levodopa, Trihexyphenidyl susceptible to anticholinergic Pramipexole, Ropinirole, adverse events including urine Bromocriptine, Amantadine, retention, confusion, Selegiline † Treatment alternatives may require prior authorization or step therapy. For the most current formulary listings, please consult: positivehealthcare.net/california/php/for-members/drug-benefit/formulary/ March 2014 hallucinations and psychotic-like symptoms Anti-Psychotics Thioridazine (Mellaril) Thioridazine has a high potential Atypical antipsychotics: Mesoridazine for CNS and extrapyramidal Risperidone, Olanzapine, adverse events. It has been Ziprasidone, Abilify, Saphris, associated with tremor, slurred quetiapine speech, muscle rigidity, dystonia, (Please note, all antipsychotics bradykinesia, and akathisia. have been associated with increased mortality when used to treat psychosis related to dementia.) Antithrombotics Dipyridamole (Persantine, NOTE: These agents been shown to be no For prevention of thromboembolic does NOT include combination better than aspirin in preventing complications of cardiac valve product with aspirin) clotting and may be considerably replacement: Warfarin Ticlopidine (Ticlid) more toxic. Dipyridamole is For prevention of stroke: associated with an increased risk Clopidogrel, Aggrenox, Aspirin of orthostatic hypotension in the elderly. Ticlopidine is associated with an increased risk of hematologic effects (e.g., neutropenia, thrombocytopenia, aplastic anemia), increased cholesterol and triglycerides, and GI bleed). Barbiturates Phenobarbital (Luminal) These medications are highly PLEASE NOTE: Patients being Mephobarbital (Mebaral) addictive and cause more adverse switched off barbiturates should Secobarbital (Seconal) effects than most other sedatives be tapered slowly over a Butabarbital (Butisol) in the elderly, greatly increasing prolonged period of time. Pentobarbital (Nembutal) cognitive impairment, confusion, For seizures: Divalproex, Butalbital and Butalbital and risk of falls. Levetiracetam, Lamotrigine, combinations (Fioricet/Codeine) Carbamazepine For sleep: Consider non- pharmacologic interventions, focusing on proper sleep hygiene. Rozerem may be considered as a safer option with less abuse † Treatment alternatives may require prior authorization or step therapy. For the most current formulary listings, please consult: positivehealthcare.net/california/php/for-members/drug-benefit/formulary/ March 2014 potential. Trazodone, Mirtazapine, Gabapentin, Nortriptyline For headache: Sumatriptan Calcium Channel Blockers Nifedipine immediate-release Immediate release nifedipine may Amlodipine, Felodipine (Adalat, Procardia) cause excessive hypotension and Extended-release Nifedipine constipation in the elderly. Cardiovascular, Other Disopyramide Disopyramide may induce heart For disopyramide: Beta-blockers, Digoxin (>0.125 mg/day) failure in elderly patients. It is also Calcium channel blockers, strongly anticholinergic, and may Flecainide cause urine retention, confusion, - For digoxin > 0.125 mg/day: In and sedation. heart failure, digoxin dosages Digoxin is substantially excreted by >0.125 mg/day have been the kidney. Because elderly associated with no additional patients are more likely to have benefit and may have increased decreased renal function, there is toxic effects. an increased risk of toxicity at doses exceeding 0.125 mg/day. Estrogens and Estrogen / Conjugated estrogen (Premarin) Elderly patients on long-term oral For Hot Flashes: Progesterone Products (Oral and Conjugated estrogen / medroxy- estrogens are at increased risk for Continuously re-evaluate the need Transdermal) progesterone (Prempro, breast and endometrial cancer. In for long-term estrogen therapy; Premphase) addition, results from the evaluate non-drug therapy. Estradiol, oral (Estrace, Femtrace) Women’s Health Initiative (WHI) Postmenopausal women should Estradiol patch (Alora, Climara, hormone trial suggest these avoid using oral estrogens for Estraderm, Estradiol, Menostar, medications may increase the risk more than 3 years. After 3 years Vivelle-Dot) of heart attack, stroke, blood clots, patients should be titrated off Estradiol / drospirenone (Angeliq) and dementia. therapy due to the risks Estradiol / levonorgestrel outweighing the benefits. (ClimaraPro) **SSRIs, Gabapentin, and Estradiol / norethindrone Venlafaxine have non-FDA labeled (CombiPatch) indications (medically accepted Estradiol / norgestimate (Prefest) use) for hot flashes. Estropipate (Ogen, Ortho- Est)Esterified estrogen (Menest) For Bone Density: Alendronate, Esterified estrogen / Actonel, Evista, Prolia methyltestosterone (Covaryx, † Treatment alternatives may require prior authorization or step therapy. For the most current formulary listings, please consult: positivehealthcare.net/california/php/for-members/drug-benefit/formulary/ March 2014 Estratest) Ethinyl estradiol / norethindrone (Activella, FemHRT) First Generation Antihistamines Brompheniramine Elderly patients are more For Allergic Rhinitis: Carbinoxamine (Arbinoxa, Palgic) susceptible to anticholinergic Desloratadine, Chlorpheniramine adverse events including urine Azelastine (nasal), Fluticasone Clemastine retention, confusion, and sedation. (nasal), Flunisolide (nasal), and Cyproheptadine Nasonex Dexbrompheniramine For N/V: Ondansetron (QL = Dexchlorpheniramine 45/30) Diphenhydramine (Benadryl) For Pruritus: Desloratadine, Doxylamine (Doxytex) Topical steroids Hydroxyzine (Vistaril) For Anxiety: SSRIs, buspirone, Promethazine (Phenergan) venlafaxine Triprolidine In addition, there are OTC Options All combination products for which coverage may vary containing one of these depending on benefit plan: medications Loratadine (Claritin) Narcotic Analgesics Meperidine (Demerol) These specific medications are less For Moderate Pain: NSAIDs*, Pentazocine / APAP (Talacen) effective than other narcotics and Tramadol, APAP with codeine Pentazocine / naloxone (Talwin have more CNS adverse effects For Severe Pain: NX) such as confusion and hallucina- Hydrocodone/APAP, Oxycodone, tions. Also, their use increases the Oxycodone/APAP, Morphine risk of falls and seizures. * Gastroprotective therapy with a PPI recommended in chronic NSAID use Oral Hypo-glycemics Chlorpropamide (Diabinese) Associated with an increased risk Glipizide Glyburide (Diabeta) of hypoglycemia compared to Glimepiride other oral diabetes agents. Chlorpropamide has also been associated with hyponatremia and SIADH in the elderly. Peripheral Vasodilators Ergoloid mesylates These agents are associated with For prevention of stroke: Isoxsuprine increased risk of orthostatic hypo- Clopidogrel, Aggrenox, Aspirin tension in the elderly. In addition, Peripheral Vascular Disease: † Treatment alternatives may require prior authorization or step therapy. For the most current formulary listings, please consult: positivehealthcare.net/california/php/for-members/drug-benefit/formulary/ March 2014 they have not been shown to be cilostazol effective for stroke prevention. For treatment of Alzheimer’s / dementia: Galantamine Donepezil Progestins Megestrol (Megace, Megace ES) Megestrol is substantially excreted Medroxyprogesterone by the kidney. Because elderly Dronabinol patients are more likely to have decreased renal function, there is an increased risk of toxicity, including adrenal suppression and thrombosis. Sedative Hypnotics Chloral hydrate Impaired motor and/or cognitive Consider non-pharmacologic Eszopiclone (Lunesta) performance after repeated interventions, focusing on proper Zolpidem (Ambien, Ambien CR) exposure. sleep hygiene. Zaleplon (Sonata) Rozerem may be considered as a safer option with less abuse potential. Trazodone Mirtazapine Gabapentin Nortriptyline Skeletal Muscle Relaxants Carisoprodol (Soma) Most muscle relaxants are poorly For Spasticity: Baclofen, Cyclobenzaprine (Flexeril) tolerated in the elderly due to
Load more

Recommended publications
  • Chronic Use of Opioid Medications Before and After Bariatric Surgery
    Supplementary Online Content Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. doi:10.1001/jama.2013.278344 eFigure. Opioid Dispensings in 60 Days Before and 60 Days After Bariatric Surgery eTable 1. Opioid Classification and Morphine Equivalents Conversion Factors for Opioids Administered by Tablet, Capsule, Liquid, Transdermal Patch, and Transmucosal Formulations eTable 2. ICD-9 Codes for Comorbid Diagnosis of Substance Abuse, Anxiety, Posttraumatic Stress Disorder, and/or Depression eTable 3. ICD-9 Codes for Inclusion and Exclusion of Chronic Pain Diagnoses eTable 4. Therapeutic Classes, Generic Names, and Selected Brand Names of Covariate Medications eTable 5. Types of Opioids Dispensed During the Year Before and the Year After Bariatric Surgery Among Presurgery Chronic Opioid Users eTable 6. Types of Opioids Used Before and After Bariatric Surgery Among 933 Individuals With Chronic Opioid Use Before Bariatric Surgery eTable 7. Unadjusted Characteristics of Chronic Opioid Users According to Whether or Not Both Presurgery and Postsurgery Body Mass Indexes (BMIs) Data Were Available eTable 8. Presurgery and Postsurgery Use of Opioids and Selected Other Analgesic and Adjunctive Pain Medication Classes Among Presurgery Chronic Opioid Users With Presurgery Chronic Pain Diagnoses This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From:
    [Show full text]
  • BUTALBITAL ANALGESICS Allzital (Butalbital-Acetaminophen
    BUTALBITAL ANALGESICS Allzital (butalbital-acetaminophen), butalbital-aspirin-caffeine, butalbital-aspirin-caffeine- codeine, butalbital-acetaminophen, butalbital-acetaminophen-caffeine, butalbital- acetaminophen-caffeine-codeine, Vanatol LQ (butalbital-acetaminophen-caffeine liquid oral solution) RATIONALE FOR INCLUSION IN PA PROGRAM Background Butalbital containing products are non-opioid analgesics that contain a combination of different drug products indicated for the relief of the symptom complex of tension (or muscle contraction) headache pain. Butalbital is a short to intermediate-acting barbiturate that works in concert with acetaminophen, an antipyretic non-salicylate agent, aspirin, a pain-relieving NSAID, and caffeine, a stimulant that works in the CNS, to decrease pain via a mechanism that isn’t well understood. Butalbital is a habit-forming drug that potentiates the effects of other commonly abuse drugs or substances like alcohol. Caffeine might help increase vasodilation and smooth muscle relaxation, while butalbital is thought to help balance the CNS stimulation caused by caffeine and produces depressant effects (1). Regulatory Status FDA approved indication: Butalbital containing products are used in the relief of the symptom complex of tension or muscle contraction headaches (2-8). Frequent use of acute medications is generally thought to cause medication-overuse headache. To decrease the risk of medication-overuse headache (“rebound headache” or “drug-induced headache”) many experts limit acute therapy to two headache days per week on a regular basis. Based on concerns of overuse, medication-overuse headache, and withdrawal, the use of butalbital-containing analgesics should be limited and carefully monitored. The Allzital limit is set to the maximum of 12 doses per day for acute treatment of 8 headaches per month as this product contains less butalbital than other products.
    [Show full text]
  • Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules
    Medication Guide Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, C III Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are: • A strong prescription pain medicine that contains an opioid (narcotic) that is indicated for the relief of the symptom complex of tension (or muscle contraction) headache, when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them. • An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death. Important information about Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules: • Get emergency help right away if you take too much Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules (overdose). When you first start taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. • Taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death. • Never give anyone else your Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules. They could die from taking it. Store Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules away from children and in a safe place to prevent stealing or abuse. Selling or giving away Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is against the law. • Get emergency help right away if you take more than 4,000 mg of acetaminophen in 1 day.
    [Show full text]
  • CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology
    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology Generic Name (Brand Name) Cidofovir (Vistide) Acetaminophen/butalbital (Allzital; Citalopram (Celexa) Bupap) Clomipramine (Anafranil) Acetaminophen/butalbital/caffeine Clonidine (Catapres; Kapvay) (Fioricet; Butace) Clorazepate (Tranxene-T) Acetaminophen/butalbital/caffeine/ Clozapine (Clozaril; FazaClo; Versacloz) codeine (Fioricet with codeine) Cyclizine (No Brand Name) Acetaminophen/caffeine (Excedrin) Cyclobenzaprine (Flexeril) Acetaminophen/caffeine/dihydrocodeine Desipramine (Norpramine) (Panlor; Trezix) Desvenlafaxine (Pristiq; Khedezla) Acetaminophen/tramadol (Ultracet) Dexmethylphenidate (Focalin) Aliskiren (Tekturna) Dextroamphetamine (Dexedrine; Amitriptyline (Elavil) ProCentra; Zenzedi) Amitriptyline and chlordiazepoxide Dextroamphetamine and amphetamine (Limbril) (Adderall) Amoxapine (Asendin) Diazepam (Valium; Diastat) Aripiprazole (Abilify) Diethylpropion (No Brand Name) Armodafinil (Nuvigil) Dimenhydrinate (Dramamine) Asenapine (Saphris) Donepezil (Aricept) Aspirin/caffeine (BC Powder; Goody Doripenem (Doribax) Powder) Doxapram (Dopram) Atomoxetine (Strattera) Doxepin (Silenor) Baclofen (Gablofen; Lioresal) Droperidol (No Brand Name) Benzphetamine (Didrex; Regimex) Duloxetine (Cymbalta) Benztropine (Cogentin) Entacapone (Comtan) Bismuth Ergotamine and caffeine (Cafergot; subcitrate/metronidazole/tetracycline Migergot) (Pylera) Escitalopram (Lexapro) Bismuth subsalicylate (Pepto-Bismol) Fluoxetine (Prozac; Sarafem)
    [Show full text]
  • Drug Plasma Half-Life and Urine Detection Window | January 2019
    500 Chipeta Way | Salt Lake City, UT 84108-1221 Phone: (800) 522-2787 | Fax: (801) 583-2712 www.aruplab.com | www.arupconsult.com DRUG PLASMA HALF-LIFE AND URINE DETECTION WINDOW | JANUARY 2019 URINE- PLASMA DRUG, DRUG METABOLITE(S)* COMMON TRADE AND STREET NAMES, NOTES DETECTION HALF-LIFEt WINDOWt STIMULANTS Benzedrine, dexedrine, Adderall, Vyvanse, speed; could be methamphetamine Amphetamine 7–34 hours 1–5 days metabolite; if so, typically < 30 percent of parent Cocaine Coke, crack; parent drug rarely observed due to short half-life 0.7–1.5 hours < 1 day Benzoylecgonine Cocaine metabolite 5.5–7.5 hours 1–2 days Desoxyn, methedrine, Vicks inhaler (D- and L-isomers not resolved; low concentrations Methamphetamine expected if the source is Vicks); selegeline (Atapryl, Carbex, Eldepryl, Zelapar) 6–17 hours 1–5 days metabolite Methylenedioxyamphetamine (MDA) MDA 11–17 hours 1–3 days Methylenedioxyethylamphetamine (MDEA) MDEA, MDE, Eve 6–11 hours 1–3 days Methylenedioxymethamphetamine (MDMA) MDMA, XTC, ecstasy, Molly 6–10 hours 1–3 days Methylphenidate Ritalin, Concerta, Focalin, Metadate, Methylin 1.4–4.2 hours < 1 day Ritalinic acid Methylphenidate metabolite 1.8–2.5 hours < 1 day Phentermine Adipex-P, Lomaira, Qsymia 19–24 hours 1–5 days OPIOIDS Buprenorphine Belbuca, Buprenex, Butrans, Suboxone, Subutex, Sublocade, Zubsolv 26–42 hours 1–7 days Norbuprenorphine, Glucuronides Buprenorphine metabolites 15–150 hours 1–14 days Included in many preparations; morphine metabolite; may be a contaminant if < 2 Codeine 1.9–3.9 hours 1–3 days percent of morphine Fentanyl Actiq, Duragesic, Fentora, Lazanda, Sublimaze, Subsys, Ionsys 3–12 hours 1–3 days Norfentanyl Fentanyl metabolite 9–10 hours 1–3 days Heroin Diacetylmorphine, dope, smack, dust; parent drug not detected.
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • Headaches in Woman
    11 Headaches in Women Randolph W. Evans Women have headaches more commonly than men. The preva- lence of migraine is 18% of women and 6% of men. This gender ratio increases from menarche, peaks at 42 years of age, and then declines. For young women the incidence of migraine with aura peaks between the ages of 12 and 13 (14.1/1,000 person- years), and migraine without aura peaks between the ages of 14 and 17 (18.9/1,000 person-years) (1). Table 11-1 provides the life- time prevalence of various headaches in women and men. Estrogen levels are a key factor in the increased prevalence of migraine in women. Evidence includes the following: migraine prevalence increases at menarche; estrogen withdrawal during menstruation is a common migraine trigger; estrogen administra- tion in oral contraceptives and hormone replacement therapy can trigger migraines; migraines typically decrease during the second and third trimesters of pregnancy, when estrogen levels are high; migraines are common immediately postpartum, with the precipi- tous drop in estrogen levels; and migraines generally improve with physiological menopause. Exactly how changes in estrogen levels influence migraine is not understood. Among numerous effects, fluctuations in estrogen levels can result in changes in prostaglandins and the uterus, prolactin release, opioid regula- tion, and melatonin secretion. These fluctuations can also cause changes in neurotransmitters, including the catecholamines, noradrenaline, serotonin, dopamine, and endorphins (2). This chapter reviews some important headache issues for women, including menstrual migraine, menopause and migraine, oral contraceptive use in migraineurs, and headaches during pregnancy and postpartum. MENSTRUAL MIGRAINE The reported prevalence of menstrual migraine varies from 4% to 73%, depending on the criteria used for the timing of the attack.
    [Show full text]
  • Barbiturates
    URINE DRUG TEST INFORMATION SHEET BARBITURATES Classification: Central nervous system depressants insomnia, anxiety or tension due to their very high (CNS Depressants) risk of physical dependence and fatal overdose. Due to the structural nature of barbiturates, the duration Background: Barbiturates are a group of drugs of action does not always correlate well with the that act as central nervous system depressants. biological half-life. Opiates, benzodiazepines and alcohol are also CNS depressants, and like their use, the effect seems to Physiological Effects: Lowered blood pressure, the user as an overall sense of calm. Barbiturates respiratory depression, fatigue, fever, impaired were introduced in 1903, dominating the sedative- coordination, nystagmus, slurred speech and ataxia hypnotic market for the first half of the twentieth century. Unfortunately, because barbiturates have Psychological Effects: Drowsiness, dizziness, unusual a relatively low therapeutic-to-toxic index and excitement, irritability, poor concentration, sedation, substantial potential for abuse, they quickly became confusion, impaired judgment, addiction, euphoria, a major health problem. Barbiturates are commonly decreased anxiety and a loss of inhibition abused for their sedative properties and widespread Toxicity: Barbiturates are especially more availability. The introduction of benzodiazepines in dangerous when abused with alcohol, opiates and the 1960s quickly supplanted the barbiturates due benzodiazepines because they act on the same to their higher safety
    [Show full text]
  • Maternal Medication and Herbal Use and Risk for Hypospadias: Data from the National Birth Defects Prevention Study, 1997--2007
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptPharmacoepidemiol Author Manuscript Drug Author Manuscript Saf. Author manuscript; available in PMC 2014 July 01. Published in final edited form as: Pharmacoepidemiol Drug Saf. 2013 July ; 22(7): 783–793. doi:10.1002/pds.3448. Maternal Medication and Herbal Use and Risk for Hypospadias: Data from the National Birth Defects Prevention Study, 1997--2007 Jennifer N. Lind1, Sarah C. Tinker1, Cheryl S. Broussard1, Jennita Reefhuis1, Suzan L. Carmichael2, Margaret A. Honein1, Richard S. Olney1, Samantha E. Parker3, and Martha M. Werler3 for the National Birth Defects Prevention Study 1National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 2Department of Pediatrics, Stanford University, Stanford, California, USA 3Slone Epidemiology Center at Boston University, Boston, Massachusetts, USA Abstract Purpose—Investigate associations between maternal use of common medications and herbals during early pregnancy and risk for hypospadias in male infants. Methods—We used data from the National Birth Defects Prevention Study, a multi-site, population-based, case-control study. We analyzed data from 1,537 infants with second-or third- degree isolated hypospadias and 4,314 liveborn male control infants without major birth defects, with estimated dates of delivery from 1997–2007. Exposure was reported use of prescription or over-the-counter medications or herbal products, from 1 month before to 4 months after conception. Adjusted odds ratios (aORs) and 95% confidence intervals (CI) were estimated using multivariable logistic regression, adjusting for maternal age, race/ethnicity, education, pre- pregnancy BMI, previous live births, maternal sub-fertility, study site, and year.
    [Show full text]
  • List of Formulary Drug Removals
    July 2021 Formulary Drug Removals Below is a list of medicines by drug class that have been removed from your plan’s formulary. If you continue using one of the drugs listed below and identified as a Formulary Drug Removal, you may be required to pay the full cost. If you are currently using one of the formulary drug removals, ask your doctor to choose one of the generic or brand formulary options listed below. Category Formulary Drug Formulary Options Drug Class Removals Acromegaly SANDOSTATIN LAR SOMATULINE DEPOT SIGNIFOR LAR SOMAVERT Allergies dexchlorpheniramine levocetirizine Antihistamines Diphen Elixir RyClora CARBINOXAMINE TABLET 6 MG Allergies BECONASE AQ flunisolide spray, fluticasone spray, mometasone spray, DYMISTA Nasal Steroids / Combinations OMNARIS QNASL ZETONNA Anticonvulsants topiramate ext-rel capsule carbamazepine, carbamazepine ext-rel, clobazam, divalproex sodium, (generics for QUDEXY XR only) divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, rufinamide, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT, XCOPRI BANZEL SUSPENSION clobazam, lamotrigine, rufinamide, topiramate, TROKENDI XR ONFI SABRIL vigabatrin ZONEGRAN carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium
    [Show full text]
  • High-Risk Medications in the Elderly
    High-Risk Medications in the Elderly The Centers for Medicare & Medicaid Services (CMS) contracted with the National Committee for Quality Assurance (NCQA) to develop clinical strategies to monitor and evaluate the quality of care provided to Medicare beneficiaries. The NCQA’s Geriatric Measurement Advisory Panel identified several categories of medications that have an increased risk of adverse effects to elderly patients. The enclosed chart identifies several key medication categories that CMS and NCQA are monitoring. In an effort to ensure patients’ safety, many of our clients have established pre-authorization protocols for those prescriptions for high risk medications in patients older than 65 years of age. Since pharmacists have a very important role in patient care, we want you to be part of this safety initiative. We strongly encourage that you contact the prescriber when your elderly patient is requesting a new or refilled prescription of a high-risk medication listed on the below chart. Category High Risk Medications Alternatives Analgesics butalbital/APAP Mild Pain: butalbital/APAP/caffeine (ESGIC, FIORICET) acetaminophen, codeine, short-term NSAIDs butalbital /APAP/caffeine/codeine Moderate/Severe Pain: butalbital/ASA/caffeine (FIORINAL) tramadol (ULTRAM), tramadol/APAP* (ULTRACET), butalbital/ASA/caffeine/codeine morphine sulfate (MS CONTIN), ketorolac (TORADOL) hydrocodone/APAP (VICODIN, etc.), oxycodone indomethacin (INDOCIN) (OXYIR), oxycodone/APAP (PERCOCET), fentanyl meperidina (DEMEROL) patch (DURAGESIC), OXYCONTIN
    [Show full text]
  • Review Memorandum
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k092268 B. Purpose for Submission: New assay C. Measurand: Barbiturates D. Type of Test: Homogeneous enzyme immunoassay – qualitative and semi- quantitative E. Applicant: Randox Laboratories Ltd. F. Proprietary and Established Names: Randox Barbiturates assay Randox Multidrug Calibrator Set Randox Multidrug Controls, Levels 1 and 2 G. Regulatory Information: 1. Regulation section: Product Code Classification Regulation Section Panel DIS Class II 21 CFR § 862.3200, 91-Toxicology Barbiturate test system DLJ Class II 21 CFR § 862.3200, 91-Toxicology Calibrators, Drug specific LAS Class I, reserved 21 CFR 862.3280 91-Toxicology Clinical Toxicology control material 1 H. Intended Use: 1. Intended use(s): See Indications for use below. 2. Indication(s) for use: Randox Barbiturates Assay: The Randox Laboratories Ltd. Barbiturates Assay is an in vitro diagnostic test for the detection of Barbiturates, in human urine on the Rx Imola and Rx Daytona. The cutoff for secobarbital is 200 ng/mL. This in vitro diagnostic device is intended for prescription use only. The semi-quantitative mode is for purpose of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS Or (2) permitting laboratories to establish quality control procedures. This assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas chromatograph/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.
    [Show full text]